David Muller, CEO of Avedro, addresses delays in the FDA’s review of the company’s riboflavin ophthalmic solution/KXL System for corneal cross-linking and discusses the considerable potential of PIXL.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
